Análisis
Published on 17 de junio de 2024 | http://doi.org/10.5867/medwave.2024.05.2781
Eficiencia y comparabilidad del uso de nuevas plataformas de evidencia para la actualización de recomendaciones: experiencia con una guía de diabetes tipo 2 en Colombia
Back to article
Distribution of the references returned for each of the eight recommendations being updated using the five search approaches.
| 1 - Add DPP4-i to metformin if out of goals & there is no CVD | 15 | 3 | 14 | 19 | 3 | 32 (39) | |
| 2 - Add SGLT2-i to metformin if out of goals & CVD is present | 2 | 2 | 5 | 3 | 6 | 11 (13) | |
| 3 - Add GLP-1 (as 3rd medication, 1 being metformin) if out of goals & BMI>30 | 6 | 1 | 3 | 5 | 4 | 14 (17) | |
| 4 - Use RAS inhibitors to prevent/reduce proteinuria | 3 | 5 | 5 | 0 | 6 | 7 (9) | |
| 5 - Assess HbA1c goals e/3-6 months (<7% or <6.5%) | 0 | 1 | 2 | 1 | 1 | 3 (4) | |
| 6 - Add insulin if HBA1C is >10% at diagnosis | 3 | 6 | 0 | 3 | 5 | 12 (15) | |
| 7 - Estimate annually GFR based on serum creatinine | 1 | 0 | 1 | 0 | 0 | 1 (1) | |
| 8 - Use monofilament test to screen for neuropathy | 0 | 2 | 0 | 0 | 0 | 2 (2) | |
| Found exclusively with this search approach (% within each contribution) | 9 (30) | 5 (25) | 9 (30) | 12 (39) | 9 (36) | ||
DPP4-i, Dipeptidyl peptidase-4 inhibitors. EBR, Evidence-based recommendation. GLP, Glucagon-like peptide. HbA1c, Glycated hemoglobin GFR: Glomerular filtration rate. RAS, Renin-angiotensin system. SGLT2-i, Sodium-glucose cotransporter-2. BMI, Body mass index.
*There were 71 single references identified, as one may inform more than evidence-based recommendation.
Source: Prepared by the authors of thsi study.